After 24 h of treatment of ALL-SIL cells with Imatinib, Nilotinib, GZD824, Torin-2 and BGT226, we detected an increase of LC3A/B II conjugated form (Figure 6A). This evidence concerns the gene MAP1LC3A and acute lymphoblastic leukemia.